| Ytd | 25.95% | |
| 1y | 15.92% |
| Open | 2.34 | Prev Close | 2.46 | Low | 2.25 | High | 2.39 | Mkt Cap | 166.70M |
| Vol | 0.00 | Avg Vol | 674.77K | EPS | -1.34 | P/E | -1.74 | Forward P/E | -1.42 |
| Beta | 0.87 | Short Ratio | 5.44 | Inst. Own | 99.79% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 2.67 | 200-d Avg | 2.39 | 1yr Est | 15.83 |
NKTX News
Nkarta (NASDAQ:NKTX) reported quarterly losses of $(0.54) per share which missed the analyst consens
Paris, France and New York, USA , July 23, 2026 (GLOBE NEWSWIRE) -- Paris, France and New York, USA,
At 2 p.m. ET on Tuesday, June 30th, Nkarta President Nadir Mahmood will take part in a fireside at t
/PRNewswire/ -- USA News Group Market Commentary - Start with the number that makes everyone do a do
Enrollment ongoing at 4 billion cell dose level (12 billion cells in 3-dose cycle) across all indica
Nkarta stock jumps after FDA backs protocol changes for ongoing NKX019 studies, enabling outpatient
SOUTH SAN FRANCISCO, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clini
SOUTH SAN FRANCISCO, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clini
Nkarta, Inc. (NASDAQ: NKTX - Get Free Report) has earned a consensus rating of "Hold" from the five
SOUTH SAN FRANCISCO, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clini
Nkarta (NASDAQ: NKTX - Get Free Report) and Bolt Biotherapeutics (NASDAQ: BOLT - Get Free Report) ar
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinic
AWM Investment Company Inc. trimmed its position in shares of Nkarta, Inc. (NASDAQ: NKTX) by 30.0% d
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinic
Nkarta Inc. remains a compelling buy as it pivots its NK cell therapy pipeline toward autoimmune dis
Enrollment now underway in second dose-escalation cohort Deep B-cell depletion observed in all pati
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinic
SOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinic
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clini
SOUTH SAN FRANCISCO, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinic
SOUTH SAN FRANCISCO, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinic
Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acqu
Shares of Cutera, Inc. (NASDAQ: CUTR) fell sharply during Friday’s session after the company report
Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCo
On Monday, 369 companies set new 52-week lows.
On Thursday, 283 companies set new 52-week lows.
On Wednesday, 220 stocks hit new 52-week lows.
On Friday, 469 companies hit new 52-week lows.
On Friday, 497 companies set new 52-week lows.
On Friday, 135 companies reached new 52-week lows.
During Friday's trading, 293 companies set new 52-week lows.
On Thursday, 241 companies hit new 52-week lows.
Monday saw 196 companies set new 52-week lows.
U.S. stocks pared losses toward the end of trading, with the Nasdaq Composite gaining around 70 poin
On Friday, 431 companies hit new 52-week lows.
On Wednesday, 160 companies hit new 52-week lows.
Tuesday morning saw 454 companies set new 52-week lows.
During Friday's session, 445 companies made new 52-week lows.
Before 10 a.m. ET on Thursday, 166 companies hit new 52-week highs.
Wednesday morning saw 335 companies set new 52-week highs.
During Thursday's morning session, 316 companies made new 52-week highs.